Serina Therapeutics shares slide on wider loss, cash burn concerns
Clinical-stage biotech reports $19.4M net loss with R&D spending surging 76% as SER-252 trial advances
Serina Therapeutics shares fell sharply Tuesday after the clinical-stage biotechnology company reported a wider net loss and accelerating cash burn, despite progress on its lead Parkinson's disease treatment.
The company posted an earnings per share loss of $1.91, missing analyst expectations of a $0.53 loss by 260%. The disappointing results come as Serina advances its SER-252 treatment into Phase 1b clinical trials, driving research and development spending 76% higher year-over-year to $13.2 million.
"The increased R&D spending reflects the advancement of our SER-252 program into registrational studies," the company said in its earnings release, noting that the Phase 1b trial initiated patient dosing in early 2026. The therapy, a POZ-apomorphine formulation designed to provide continuous dopaminergic stimulation, aims to reduce motor complications in advanced Parkinson's disease patients.
The company's net loss widened to $19.4 million for the full year 2025, compared with $11.1 million in the prior year. With no product revenue—Serina is a pure-play clinical-stage company—cash burn remains a critical concern for investors monitoring the path to potential commercialization.
Cash and cash equivalents stood at $3.1 million at year-end, a precarious position even after the company raised $16 million in financing. The limited runway raises questions about Serina's ability to fund ongoing operations and clinical trials without additional capital raises, which could further dilute existing shareholders.
The financial challenges contrast with the scientific progress on SER-252. The U.S. Food and Drug Administration cleared the company's Investigational New Drug application in 2026, enabling the Phase 1b registrational study to proceed. The FDA has also expressed support for the program's eligibility for a 505(b)(2) New Drug Application pathway, which could streamline regulatory review.
That regulatory path wasn't without hurdles. In November 2025, the FDA placed a clinical hold on the SER-252 IND application, requesting additional information related to an excipient in the formulation. The company resolved those concerns and the hold was lifted, allowing the trial to proceed.
The Phase 1b study is being conducted across sites in Australia and the United States, with Serina collaborating with Parkinson's Australia and Neuroscience Trials Australia for participant recruitment. The company anticipates reviewing initial safety data from the first dosing cohort later in 2026, with potential progression to a second cohort in the third quarter.
Analysts have set a target price of $11.00 per share, suggesting significant upside potential if SER-252 demonstrates clinical success. However, the company's current market capitalization of approximately $27 million reflects investor skepticism about the path forward, particularly given the competitive landscape for Parkinson's disease treatments.
Serina's proprietary polymer-based drug delivery platform, which enhances therapeutic efficacy, remains central to its strategy. The company believes this technology could support a broader pipeline beyond SER-252, though all candidates remain in early-stage development.
The stock's 52-week range of $1.22 to $7.92 underscores the volatility typical of clinical-stage biotechs, where binary clinical trial outcomes can drive dramatic price swings. Tuesday's decline reflects investor concerns about whether Serina's current cash position can sustain operations long enough to reach meaningful clinical readouts that could justify additional financing on favorable terms.
With the SER-252 Phase 1b trial now underway, investors will be closely watching for safety data updates later this year. Those results will be critical not only for determining the therapy's therapeutic potential but also for the company's ability to secure the funding needed to continue its development programs.